An optimised method for cryopreservation of human hepatocytes.

Institute of Liver Studies, King's College London School of Medicine London, UK.
Methods in Molecular Biology (Impact Factor: 1.29). 02/2009; 481:25-34. DOI: 10.1007/978-1-59745-201-4_3
Source: PubMed

ABSTRACT Successful cryopreservation of hepatocytes is essential for their use in hepatocyte transplantation. Cryopreservation allows hepatocytes to be available for emergency treatment of acute liver failure and also for planned treatment of liver-based metabolic disorders. In addition, cryopreservation of human hepatocytes can facilitate their use in metabolism and toxicity studies. Cryopreservation can adversely affect the viability and function, especially reduce the attachment efficiency, of hepatocytes on thawing.The cryopreservation process can be divided into steps so that improvements can be made on the 'standard' protocols that are followed in some laboratories. These steps are as follows: pre-incubation of cells; freezing solution, cryoprotectants and cytoprotectants; freezing process; storage; thawing; post-thawing culture. This chapter presents an optimised protocol for cryopreservation of human hepatocytes as developed at King's College Hospital.

Download full-text


Available from: Robin D Hughes, Apr 16, 2015
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Orthotopic liver transplantation is the most common treatment for patients with end-stage liver failure. However, liver transplantation is greatly limited by a donor shortage. Liver tissue engineering may offer a promising strategy to solve this problem by providing transplantable, bioartificial livers. Diverse types of cells, biomaterials, and growth factor delivery systems have been tested for efficient regeneration of liver tissues that possess hepatic functions comparable to native livers. This article reviews recent advances in liver tissue engineering and describes cell sources, biomaterial scaffolds, and growth factor delivery systems that are currently being used to improve the regenerative potential of tissue-engineered livers.
    Biotechnology and Bioprocess Engineering 06/2012; 17(3). DOI:10.1007/s12257-012-0047-9 · 1.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ischemic preconditioning (IPC) protects liver graft function following ischemia in liver transplantation and liver resection. The aim of this study was to assess the advantages and any potential disadvantages of liver IPC prior to isolation for rat hepatocytes during isolation and cryopreservation. After isolating and thawing the cryopreserved hepatocytes after 14 and 28 d, cell viability, efficiency, and lactate dehydrogenase (LDH) levels in preserve solution were examined for every group. Groups treated with IPC had better cell viability determination, assessment of plating efficiency and lactate dehydrogenase (LDH) assay than Group without IPC, suggesting that IPC prior to isolation may have a significant protective effect on hepatocytes subjected to isolation and short period cryopreservation.
    Science in China Series C Life Sciences 09/2009; 52(9):836-40. DOI:10.1007/s11427-009-0113-5 · 1.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The first indication of hepatocyte transplantation is inborn liver-based metabolic disorders. Among these, urea cycle disorders leading to the impairment to detoxify ammonia and Crigler-Najjar Syndrome type I, a deficiency in the hepatic UDP-glucuronosyltransferase 1A1 present the highest incidence. Metabolically qualified human hepatocytes are required for clinical infusion. We proposed fast and sensitive procedures to determine their suitability for transplantation. For this purpose, viability, attachment efficiency, and metabolic functionality (ureogenic capability, cytochrome P450, and phase II activities) are assayed prior to clinical cell infusion to determine the quality of hepatocytes. Moreover, the evaluation of urea synthesis from ammonia and UDP-glucuronosyltransferase 1A1 activity, a newly developed assay using beta-estradiol as substrate, allows the possibility of customizing cell preparation for receptors with urea cycle disorders or Crigler-Najjar Syndrome type I. Sources of human liver and factors derived from the procurement of the liver sample (warm and cold ischemia) have also been investigated. The results show that grafts with a cold ischemia time exceeding 15 h and steatosis should not be accepted for hepatocyte transplantation. Finally, livers from non-heart-beating donors are apparently a potential suitable source of hepatocytes, which could enlarge the liver donor pool.
    Cell Transplantation 09/2009; 19(1):21-8. DOI:10.3727/096368909X474267 · 3.57 Impact Factor
Show more